AstraZeneca fails another Phase III clinical trial (Lupus)

AstraZeneca’s shares have declined almost 2% as the group led by Pascal Soriot has announced that the investigational therapy anifrolumab had failed to reach its primary endpoints in the Phase III Tulip clinical trial conducted on 460 patients with systemic lupus erythematosus (SLE). Anifrolumab is a monoclonal antibody targeting I-interferon receptors, and was one of the few investigational, non-oncological therapies on which the group was working. Investors are now wondering whether AstraZeneca will be able to reach the ambitious targets it has set with a pipeline completely focused on oncology.